biote Corp. (BTMD)
| Market Cap | 32.86M |
| Revenue (ttm) | 164.96M |
| Net Income (ttm) | -969,000 |
| Shares Out | 8.40M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | 7.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,050 |
| Open | 3.73 |
| Previous Close | 5.35 |
| Day's Range | 5.34 - 5.80 |
| 52-Week Range | 2.00 - 10.53 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.54 (+88.55%) |
| Earnings Date | Mar 28, 2023 |
About BTMD
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for BTMD stock is "Buy." The 12-month stock price forecast is $10.54, which is an increase of 88.55% from the latest price.
News
Biote Reports Fourth Quarter and Full Year 2022 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for...
Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report
IRVING, Texas--(BUSINESS WIRE)---- $BTMD #antiaging--In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” aft...
Biote to Present at 35th Annual Roth Conference
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announc...
Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announce...
Biote Announces Closing of Secondary Offering of 8,500,000 Shares of Common Stock Including Full Exercise of the Underwriters' Over-Allotment Option
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announ...
Biote Announces Pricing of Secondary Offering of Common Stock
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announ...
Biote to Present at Jefferies London Healthcare Conference
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announc...
Biote Reports Third Quarter Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third...
Biote Appoints Debby Morris to Board of Directors
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announc...
Biote Schedules Third Quarter 2022 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announce...
Biote Releases Updated Corporate Presentation for October 2022
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today rel...
Biote Announces Strategic Partnership with IMAC Holdings, Inc.
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ann...
Biote Announces Approval to Relist on The Nasdaq Stock Market
IRVING, Texas--(BUSINESS WIRE)--Biote Announces Approval to Relist on The Nasdaq Stock Market
Biote Appoints Samar Kamdar as Chief Financial Officer
IRVING, Texas--(BUSINESS WIRE)--Biote Appoints Samar Kamdar as Chief Financial Officer
Biote Issues Correction to Second Quarter Operating Loss and Net Income
IRVING, Texas--(BUSINESS WIRE)--Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Seco...
Biote Reports Second Quarter 2022 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the second quarter ...
Biote to Report Second Quarter 2022 Financial Results on August 9, 2022 and Host Conference Call on August 10, 2022
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financia...
Biote Appoints Ross W. McQuivey, M.D.
IRVING, Texas--(BUSINESS WIRE)--Biote Appoints Ross W. McQuivey, M.D. as Chief Medical Officer
Biote Announces Participation in the Jefferies Healthcare Conference 2022
IRVING, Texas--(BUSINESS WIRE)--Biote Announces Participation in the Jefferies Healthcare Conference 2022
National Women in the Workplace Survey: Women with Menopausal Symptoms Suffer in Silence in the Workplace
IRVING, Texas--(BUSINESS WIRE)---- $BTMD #hrt--4 in 10 working women in U.S. ages 50-65 say menopause symptoms have interfered with their work performance at least once a week.
Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
IRVING, Texas--(BUSINESS WIRE)--Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry
Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III
IRVING, Texas--(BUSINESS WIRE)--BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition...
Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (the "Company") today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit...
ARKO Stock: 13 Things to Know As Convenience Store Play Arko Starts Trading
ARKO stock just started trading after the Arko Holdings SPAC merger closed. Here's what investors should know now.
Haymaker Acquisition Corp. II, ARKO Holdings Ltd. and GPM Investments, LLC Close Business Combination under New Company ARKO Corp.
ARKO Corp. to trade on the Nasdaq Stock Market under “ARKO” ARKO Corp. to trade on the Nasdaq Stock Market under “ARKO”